Barclays lowered the firm’s price target on Tenet Healthcare (THC) to $161 from $190 and keeps an Overweight rating on the shares post the Q4 report. The firm looks for Tenet to increase buybacks against an elevated backdrop of policy uncertainty and volatility.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare’s Strong Financial Performance and Strategic Shift Drive Buy Rating
- Mixed Performance and Future Outlook Lead to Cautious Hold Rating for Tenet Healthcare
- Tenet Healthcare Corp. Reports Strong 2024 Results
- Morning Movers: CVS Health jumps following fourth quarter earnings
- Tenet Healthcare reports Q4 adjusted EPS $3.44, consensus $2.83